Mink Therapeutics Inc is a biotechnology company focused on developing innovative therapeutic solutions to address unmet medical needs
The company specializes in creating advanced treatments targeting various diseases and conditions by leveraging cutting-edge technologies in drug discovery and development. With a commitment to enhancing patient outcomes, Mink Therapeutics aims to bring novel therapies from the lab to the clinic, fostering improvements in healthcare through scientific research and collaboration.
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, today announced that it has received formal notice from Nasdaq confirming that the Company has regained compliance with both the minimum bid price and market value of listed securities requirements for continued listing on The Nasdaq Capital Market. As a result, MiNK now meets all Nasdaq Capital Market listing requirements, and the matter has been closed.
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company’s ongoing Phase 2 study testing AgenT-797 in combination with Agenus’ lead therapeutic combination, botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastric cancer (NCT06251973).
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium in San Francisco, California.
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the third quarter 2024. MiNK will host a conference call and webcast at 8:30 a.m. ET.
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), emerging threats, and immune related diseases.
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies and Autonomous Therapeutics, Inc. (Autonomous), a leader developing first-in-class, disease-activated RNA medicines, announced a research collaboration aimed at effectively targeting and treating metastatic tumors.
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 29th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new preclinical data from MiNK’s iNKT cell programs, agenT-797 and PRAME-TCR.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer, will participate in a fireside chat and investor one-on-ones at the upcoming H.C. Wainwright 26th Annual Global Investment Conference on September 9-11th. The fireside chat will take place at 7:00 a.m. ET on Monday, September 9th.
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the second quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update.
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQINKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced today that it has regained compliance with the Nasdaq Capital Market’s market value of listed securities (“MVLS”) requirement.
